About GliaCure

GliaCure is focused on the development of novel therapies for neurological and neuropsychiatric disorders based on glia targets. GliaCure was founded in 2011 and is based on discoveries by its scientific founder, Philip Haydon, Ph.D., of Tufts University. Professor Haydon has partnered with Michael Szulczewski, who successfully co-founded the imaging company Prairie Technologies, Inc. Their complementary skills in academia and industry provide a solid basis for success in this new venture.

GliaCure is a pioneer in the development of novel therapeutics aimed at treating neurological and neuropsychiatric disorders of the brain. The company’s approaches are based on glial targets, a cell type in the brain that has previously been overlooked in drug discovery…more »

Latest News



GliaCure Highlighted in ADDF Annual Report

GliaCure’s compound GC021109 and its successful Phase 1 clinical trial were highlighted in the Alzheimer’s Drug Discovery Foundation (ADDF) Annual Report, issued in late 2017. The report points out that there is growing research to suggest that anti-inflammatory approaches may hold the key to treating the underlying causes of Alzheimer’s disease, and shows that GC021109...more »